315 related articles for article (PubMed ID: 31697806)
1. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.
Di Buduo CA; Abbonante V; Marty C; Moccia F; Rumi E; Pietra D; Soprano PM; Lim D; Cattaneo D; Iurlo A; Gianelli U; Barosi G; Rosti V; Plo I; Cazzola M; Balduini A
Blood; 2020 Jan; 135(2):133-144. PubMed ID: 31697806
[TBL] [Abstract][Full Text] [Related]
2. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
[TBL] [Abstract][Full Text] [Related]
3. CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes.
Olschok K; Han L; de Toledo MAS; Böhnke J; Graßhoff M; Costa IG; Theocharides A; Maurer A; Schüler HM; Buhl EM; Pannen K; Baumeister J; Kalmer M; Gupta S; Boor P; Gezer D; Brümmendorf TH; Zenke M; Chatain N; Koschmieder S
Stem Cell Reports; 2021 Nov; 16(11):2768-2783. PubMed ID: 34678208
[TBL] [Abstract][Full Text] [Related]
4. The role of calreticulin mutations in myeloproliferative neoplasms.
Araki M; Komatsu N
Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
[TBL] [Abstract][Full Text] [Related]
5. Mutant calreticulin in myeloproliferative neoplasms.
How J; Hobbs GS; Mullally A
Blood; 2019 Dec; 134(25):2242-2248. PubMed ID: 31562135
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Imai M; Araki M; Komatsu N
Int J Hematol; 2017 Jun; 105(6):743-747. PubMed ID: 28470469
[TBL] [Abstract][Full Text] [Related]
8. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
[TBL] [Abstract][Full Text] [Related]
9. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
Edahiro Y; Araki M; Komatsu N
Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
[TBL] [Abstract][Full Text] [Related]
10. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
[TBL] [Abstract][Full Text] [Related]
11. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
12. Calreticulin mutations in myeloproliferative neoplasms.
Shide K
Int Rev Cell Mol Biol; 2021; 365():179-226. PubMed ID: 34756244
[TBL] [Abstract][Full Text] [Related]
13. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
Nomani L; Bodo J; Zhao X; Durkin L; Loghavi S; Hsi ED
Am J Clin Pathol; 2016 Oct; 146(4):431-8. PubMed ID: 27686170
[TBL] [Abstract][Full Text] [Related]
14. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.
Pietra D; Rumi E; Ferretti VV; Di Buduo CA; Milanesi C; Cavalloni C; Sant'Antonio E; Abbonante V; Moccia F; Casetti IC; Bellini M; Renna MC; Roncoroni E; Fugazza E; Astori C; Boveri E; Rosti V; Barosi G; Balduini A; Cazzola M
Leukemia; 2016 Feb; 30(2):431-8. PubMed ID: 26449662
[TBL] [Abstract][Full Text] [Related]
15. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
Araki M
Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
[TBL] [Abstract][Full Text] [Related]
16. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
[TBL] [Abstract][Full Text] [Related]
17. Mutant calreticulin: when a chaperone becomes intrusive.
Cazzola M
Blood; 2016 Mar; 127(10):1219-21. PubMed ID: 26965919
[TBL] [Abstract][Full Text] [Related]
18. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
19. Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations.
Ali H; Puccio I; Akarca AU; Bob R; Pomplun S; Keong Wong W; Gupta R; Sekhar M; Lambert J; Al-Masri H; Stein H; Marafioti T
Int J Exp Pathol; 2021 Feb; 102(1):45-50. PubMed ID: 32929772
[TBL] [Abstract][Full Text] [Related]
20. The Calreticulin gene and myeloproliferative neoplasms.
Clinton A; McMullin MF
J Clin Pathol; 2016 Oct; 69(10):841-5. PubMed ID: 27354406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
